Name
GGS01-10 - HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer (China)
Date & Time
Wednesday, December 20, 2023
Speakers
Virtual Session Link